ABINGDON HEALTH PLC - Final results for the year ended 30 June 2026

Abingdon Health grew FY26 revenue 30% to £11m and hit first EBITDA profit by pivoting to end-to-end diagnostic development and manufacturing.

• Revenue up 30%: Abingdon Health's FY26 revenue rose to over £11 million, hitting its first adjusted EBITDA profit in H2.
• End-to-end pivot: The firm now handles the full pipeline—R&D, regulatory approval, and manufacturing—for rapid diagnostic clients rather than just printing tests.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.